Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?
09:10am, Wednesday, 10'th Jul 2024
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength
Why Kymera Therapeutics Stock Is Soaring Today
01:30pm, Tuesday, 09'th Jul 2024
Sanofi plans to expand phase 2 clinical studies evaluating Kymera's KT-474. This move could accelerate pivotal testing for the potential skin treatment.
Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies
11:01am, Tuesday, 09'th Jul 2024
Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.
Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug
10:55am, Tuesday, 09'th Jul 2024
Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its experimental drug to treat certain autoimmune skin diseases.
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
07:00am, Tuesday, 09'th Jul 2024
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
04:05pm, Monday, 08'th Jul 2024
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
07:00am, Friday, 14'th Jun 2024
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
08:00am, Saturday, 01'st Jun 2024
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
07:00am, Wednesday, 29'th May 2024
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
05:00pm, Thursday, 23'rd May 2024
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
11:20am, Wednesday, 22'nd May 2024
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
10:00am, Tuesday, 14'th May 2024
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
07:00am, Wednesday, 08'th May 2024
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
10:51am, Monday, 06'th May 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IM
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
11:01am, Friday, 03'rd May 2024
Kymera (KYMR) reports a narrower-than-expected loss in the first quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
